Accredited Investors’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $769K | Sell |
2,123
-33
| -2% | -$11.3K | 0.03% | 134 |
|
|
2026
Q1 | $759K | Sell |
2,156
-138
| -6% | -$49.2K | 0.04% | 127 |
|
|
2025
Q4 | $751K | Buy |
2,294
+14
| +0.6% | +$4.44K | 0.04% | 129 |
|
|
2025
Q3 | $643K | Buy |
2,280
+117
| +5% | +$33.9K | 0.04% | 129 |
|
|
2025
Q2 | $604K | Sell |
2,163
-1
| -0% | -$283 | 0.04% | 127 |
|
|
2025
Q1 | $674K | Buy |
2,164
+37
| +2% | +$10.9K | 0.04% | 108 |
|
|
2024
Q4 | $554K | Buy |
2,127
+4
| +0.2% | +$1.19K | 0.03% | 123 |
|
|
2024
Q3 | $684K | Buy |
2,123
+3
| +0.1% | +$981 | 0.04% | 111 |
|
|
2024
Q2 | $662K | Buy |
2,120
+4
| +0.2% | +$1.18K | 0.04% | 107 |
|
|
2024
Q1 | $602K | Buy |
2,116
+678
| +47% | +$198K | 0.04% | 113 |
|
|
2023
Q4 | $414K | Sell |
1,438
-33
| -2% | -$8.99K | 0.03% | 132 |
|
|
2023
Q3 | $395K | Buy |
1,471
+2
| +0.1% | +$499 | 0.03% | 127 |
|
|
2023
Q2 | $326K | Sell |
1,469
-74
| -5% | -$17.2K | 0.02% | 138 |
|
|
2023
Q1 | $373K | Buy |
1,543
+2
| +0.1% | +$491 | 0.03% | 128 |
|
|
2022
Q4 | $405K | Buy |
1,541
+36
| +2% | +$9.65K | 0.03% | 120 |
|
|
2022
Q3 | $339K | Sell |
1,505
-283
| -16% | -$68.6K | 0.04% | 122 |
|
|
2022
Q2 | $435K | Buy |
1,788
+493
| +38% | +$121K | 0.05% | 108 |
|
|
2022
Q1 | $313K | Sell |
1,295
-10
| -0.8% | -$2.3K | 0.03% | 142 |
|
|
2021
Q4 | $293K | Buy |
1,305
+13
| +1% | +$2.74K | 0.03% | 148 |
|
|
2021
Q3 | $275K | Sell |
1,292
-58
| -4% | -$13.3K | 0.03% | 142 |
|
|
2021
Q2 | $329K | Buy |
1,350
+208
| +18% | +$51.2K | 0.03% | 124 |
|
|
2021
Q1 | $284K | Sell |
1,142
-166
| -13% | -$39.6K | 0.04% | 133 |
|
|
2020
Q4 | $301K | Buy |
1,308
+249
| +24% | +$57.4K | 0.05% | 120 |
|
|
2020
Q3 | $269K | Buy |
1,059
+92
| +10% | +$22.8K | 0.06% | 115 |
|
|
2020
Q2 | $228K | Sell |
967
-732
| -43% | -$167K | 0.05% | 115 |
|
|
2020
Q1 | $344K | Sell |
1,699
-2
| -0.1% | -$437 | 0.08% | 101 |
|
|
2019
Q4 | $410K | Hold |
1,701
| – | – | 0.07% | 97 |
|
|
2019
Q3 | $329K | Sell |
1,701
-137
| -7% | -$26.3K | 0.06% | 103 |
|
|
2019
Q2 | $339K | Sell |
1,838
-29
| -2% | -$5.19K | 0.07% | 104 |
|
|
2019
Q1 | $355K | Buy |
1,867
+311
| +20% | +$59.4K | 0.07% | 94 |
|
|
2018
Q4 | $303K | Hold |
1,556
| – | – | 0.07% | 94 |
|
|
2018
Q3 | $323K | Sell |
1,556
-75
| -5% | -$14.8K | 0.08% | 88 |
|
|
2018
Q2 | $301K | Sell |
1,631
-38
| -2% | -$6.72K | 0.08% | 86 |
|
|
2018
Q1 | $285K | Buy |
1,669
+104
| +7% | +$19.1K | 0.08% | 83 |
|
|
2017
Q4 | $272K | Buy |
1,565
+9
| +0.6% | +$1.59K | 0.08% | 94 |
|
|
2017
Q3 | $290K | Buy |
1,556
+6
| +0.4% | +$1.06K | 0.08% | 90 |
|
|
2017
Q2 | $267K | Hold |
1,550
| – | – | 0.07% | 82 |
|
|
2017
Q1 | $254K | Hold |
1,550
| – | – | 0.06% | 86 |
|
|
2016
Q4 | $227K | Sell |
1,550
-5
| -0.3% | -$753 | 0.06% | 89 |
|
|
2016
Q3 | $259K | Buy |
1,555
+12
| +0.8% | +$2.03K | 0.07% | 81 |
|
|
2016
Q2 | $235K | Buy |
1,543
+38
| +3% | +$5.91K | 0.06% | 84 |
|
|
2016
Q1 | $226K | Hold |
1,505
| – | – | 0.06% | 84 |
|
|
2015
Q4 | $245K | Buy |
+1,505
| New | +$237K | 0.06% | 80 |
|
|
2015
Q3 | – | Sell |
-1,355
| Closed | -$209K | – | 85 |
|
|
2015
Q2 | $209K | Hold |
1,355
| – | – | 0.05% | 73 |
|
|
2015
Q1 | $217K | Sell |
1,355
-40
| -3% | -$6.3K | 0.06% | 69 |
|
|
2014
Q4 | $223K | Buy |
+1,395
| New | +$217K | 0.07% | 69 |
|
Other funds holding AMGN
Accredited Investors's AMGN Position: Q2 2026 in Review
Accredited Investors reduced its Amgen (AMGN) stake by 1.5% in Q2 2026, selling an estimated $11.3K and leaving 2,123 shares worth $769K. The position accounts for 0.03% of the portfolio, ranked #134.
Accredited Investors first reported a position in AMGN in Q4 2014 and has held it in 46 quarters since. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.
- Accredited Investors held 2,123 shares of Amgen worth $769K as of Q2 2026.
- Accredited Investors sold 33 Amgen shares in Q2 2026, an estimated $11.3K.
- Amgen made up 0.03% of Accredited Investors's portfolio in Q2 2026, its #134 holding.
- Accredited Investors first reported a position in Amgen in Q4 2014 and has held it in 46 quarters since.
- 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.
Based on Accredited Investors's 13F filing for Q2 2026, filed 21 Jul 2026.